ClinicalTrials.gov
public full text
Public Domain
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease.#288590
- Comprehensive Support for Alzheimer's Disease Caregivers#896819
- ADDIA Proof-of-Performance Clinical Study#834477
- An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US#836959
- A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)#908871
Record · ID 837540
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive